🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Caitlin R. Rausch

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-4166-5717
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6
N/A
6.4DataRank · unranked
334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Cancer(2021)10.1002/cncr.33689
N/A
3.9DataRank · unranked
158 citations

Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch +14 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717
N/A
3.2DataRank · unranked
82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

Clinical Infectious Diseases(2020)10.1093/cid/ciaa358
N/A
3.1DataRank · unranked
77 citations

David McCue, Sebastian Wurster, Nathan P. Wiederhold, Marina Konopleva, Tapan M. Kadia +18 more

Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia

American Journal of Hematology(2021)10.1002/ajh.26122
N/A
1.4DataRank · unranked
25 citations

Abhishek Maiti, Courtney D. DiNardo, Sanam Loghavi, Naval Daver, Tapan M. Kadia +11 more

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1973675
N/A
0.308DataRank · unranked
5 citations

Abhishek Maiti, Courtney D. DiNardo, Wei Qiao, Jing Ning, Sanam Loghavi +13 more

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Cancer(2025)10.1002/cncr.35840
N/A
0.104DataRank · unranked
1 citations

Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour +13 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w
N/A
0DataRank · unranked
126 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

Cancer(2021)10.1002/cncr.33814
N/A
0DataRank · unranked
51 citations

Courtney D. DiNardo, Wei Qiao, Tapan M. Kadia, Elias Jabbour, Caitlin R. Rausch +18 more

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Blood Cancer Journal(2021)10.1038/s41408-021-00453-z
N/A
0DataRank · unranked
45 citations

Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver +12 more

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7519
N/A
0DataRank · unranked
8 citations

Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Caitlin R. Rausch, Kiran Naqvi +15 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061
N/A
0DataRank · unranked
103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.12.016
N/A
0DataRank · unranked
23 citations

Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall +11 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569
N/A
0DataRank · unranked
174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more